

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 51/00, A61M 36/14</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/56370</b> <b>(43) International Publication Date:</b> 28 September 2000 (28.09.00)
<b>(21) International Application Number:</b> PCT/US00/07398 <b>(22) International Filing Date:</b> 20 March 2000 (20.03.00)  <b>(30) Priority Data:</b> 09/273,100 19 March 1999 (19.03.99) US  <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US 09/273,100 (CIP) Filed on 19 March 1999 (19.03.99)  <b>(71) Applicant (for all designated States except US):</b> MICRO THERAPEUTICS, INC. [US/US]; 2 Goodyear, Irvine, CA 92618 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> RICCI, Charlie [US/US]; 23836 Sheffield, Mission Viejo, CA 92692 (US). DOL-MATCH, Bart [US/US]; 3160 Roundwood Road, Hunting Valley, OH 44022 (US). CRAGG, Andrew, H. [US/US]; 4502 Edina Boulevard, Edina, MN 55424 (US). GREFF, Richard, J. [US/US]; 2891 Alton Drive, St. Pete Beach, FL 33706 (US).		<b>(74) Agents:</b> SWISS, Gerald, F. et al.; Burns, Doane, Swecker & Mathis, LLP, P.O. Box 1404, Alexandria, VA 22313-1404 (US).  <b>(81) Designated States:</b> AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHODS FOR INHIBITING THE FORMATION OF ENDOLEAKS ASSOCIATED WITH ENDOVASCULAR REPAIR OF ABDOMINAL AORTIC ANEURYSMS		
<b>(57) Abstract</b>  Disclosed are methods for inhibiting endoleak formation associated with endovascular repair of abdominal aortic aneurysms.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**METHODS FOR INHIBITING THE FORMATION OF ENDOLEAKS  
ASSOCIATED WITH ENDOVASCULAR REPAIR OF ABDOMINAL  
AORTIC ANEURYSMS**

**CROSS-REFERENCE TO RELATED APPLICATIONS**

5           This application is a continuation-in-part of pending U.S. application  
Serial No. 09/273,100, filed March 19, 1999, which application is  
incorporated herein by reference in its entirety.

**BACKGROUND OF THE INVENTION**

**Field of the Invention**

10           This invention is directed to methods for inhibiting the formation of  
endoleaks associated with endovascular repair of abdominal aortic aneurysms.  
In one embodiment, this invention is directed to methods for inhibiting  
endoleaks arising from retrograde bleeding from blood vessels associated with  
the aneurysmal sac such as the lumbar and inferior mesenteric arteries into the  
15   aneurysm sac which permit blood flow through it after endovascular repair of  
abdominal aortic aneurysms.

Specifically, in this embodiment, the methods of this invention involve  
the *in situ* embolization of blood vessels associated with the aneurysmal sac  
prior to placement of an endovascular prostheses in the abdominal aorta.

20   Embolization of the blood vessels is achieved by injection of a biocompatible  
fluid composition into these vessels in a sufficient amount such that upon *in  
situ* solidification of this composition, blood circulation through these blood  
vessels and the aneurysmal sac is arrested. Preferably, the biocompatible fluid

-2-

composition comprises a contrast agent to allow the clinician to visualize the embolization process.

### References

The following publications, patent applications and patents are cited in this application as superscript numbers:

- 5                   <sup>1</sup>       May, et al., "Concurrent Comparison of Endoluminal Versus Open Repair in the Treatment of Abdominal Aortic Aneurysms: Analysis of 303 Patients by Life Table Method", J. Vasc. Surg. 27(2):213-221 (1998)
- 10                  <sup>2</sup>       White, et al., J. Endovasc. Surg., 3:124-125 (1996)
- <sup>3</sup>       Marty, et al., "Endoleak After Endovascular Graft Repair of Experimental Aortic Aneurysms: Does Coil Embolization with Angiographic "Seal" Lower Intraaneurysmal Pressure", J. Vasc. Surg., 27(3):454-462 (1998)
- 15                  <sup>4</sup>       Money, et al., "Perioperative Charge Comparison and Endovascular Abdominal Aortic Aneurysm Repair", JPV 1.1-1.2, Presented at the 6<sup>th</sup> Annual Symposium on Current Issues and New Techniques in Interventional Radiology at New York, New York in November, 1998
- 20                  <sup>5</sup>       Beebe, et al., "Current Status of the United States Vanguard<sup>TM</sup> Endograft Trial", JPVA 2.1-2.3, Presented at the 6<sup>th</sup> Annual Symposium on Current Issues and New Techniques in Interventional Radiology at New York, New York in November, 1998
- 25                  <sup>6</sup>       Hopkinson, et al., "Current Critical Problems, New Horizons and Techniques in Vascular and Endovascular Surgery", JPVI 4.1-4.2, Presented at the 6<sup>th</sup> Annual Symposium on Current Issues and New Techniques in Interventional Radiology at New York, New York in November, 1998
- 30                  <sup>7</sup>       Kinugasa, et al., "Direct Thrombosis of Aneurysms with Cellulose Acetate Polymer", J. Neurosurg., 77:501-507 (1992)

-3-

- 8 Greff, et al., U.S. Patent No. 5,667,767 for "*Novel Compositions for Use in Embolizing Blood Vessels*", issued September 16, 1997
- 5 9 Greff, et al., U.S. Patent No. 5,580,568 for "*Cellulose Diacetate Compositions for Use in Embolizing Blood Vessels*", issued December 3, 1996
- 10 10 Kinugasa, et al., "*Early Treatment of Subarachnoid Hemorrhage After Preventing Rerupture of an Aneurysm*", J. Neurosurg., 83:34-41 (1995)
- 10 11 Kinugasa, et al., "*Prophylactic Thrombosis to Prevent New Bleeding and to Delay Aneurysm Surgery*", Neurosurg., 36:661 (1995)
- 15 12 Taki, et al., "*Selection and Combination of Various Endovascular Techniques in the Treatment of Giant Aneurysms*", J. Neurosurg., 77:37-42 (1992)
- 20 13 Evans, et al., U.S. Patent Application Serial No. 08/802,252 for "*Novel Compositions for Use in Embolizing Blood Vessels*", filed February 19, 1997.
- 20 14 Castaneda-Zuniga, et al., *Interventional Radiology*, in Vascular Embolotherapy, Part 1, 1:9-32, Williams & Wilkins, Publishers (1992)
- 25 15 Rabinowitz, et al., U.S. Patent No. 3,527,224, for "*Method of Surgically Bonding Tissue Together*", issued September 8, 1970
- 25 16 Hawkins, et al., U.S. Patent No. 3,591,676, for "*Surgical Adhesive Compositions*", issued July 6, 1971
- 30 17 Parodi, "*Endovascular AAA Stent Grafts: Technology, Training and Proper Patient Selection*", JPVA 1.1-1.2 Presented at the 6<sup>th</sup> Annual Symposium on Current Issues and New Techniques in Interventional Radiology at New York, New York in November, 1998

-4-

18 van Schie, et al., "Successful Embolization of Persistent  
Endoleak from a Patent Inferior Mesenteric Artery", J.  
Endovasc. Surg., 4:312-315 (1997)

5 19 Walker, et al., "A Study of the Patency of the Inferior  
Mesenteric and Lumbar Arteries in the Incidence of Endoleak  
Following Endovascular Repair of Infra-renal Aortic  
Eneurysms", Clinical Radiology, 53:593-595 (1998)

All of the above publications, patent applications and patents are herein  
incorporated by reference in their entirety to the same extent as if each  
10 individual publication, patent application or patent was specifically and  
individually indicated to be incorporated by reference in its entirety.

#### State of the Art

Abdominal aortic aneurysms (AAA) represents a serious medical  
challenge and, when left untreated, eventual rupture of the aneurysm has  
15 significant morbidity associated therewith. When feasible, open surgery to  
repair the aortic aneurysm has been shown to be clinically successful.<sup>1</sup>  
However, open surgery is often not feasible especially in patients suffering  
from severe cardiac disease, renal disease or other conditions which contra-  
indicate open surgery. For example, conventional exposure of the infrarenal  
20 aorta necessitates a large abdominal incision, mobilization of the abdominal  
viscera, and retroperitoneal dissection which are associated with complications  
such as renal failure, pseudoaneurysms and bleeding. Infrarenal aortic  
clamping is also associated with an increased cardiac demand including an  
increase in left ventricular end diastolic volume and may be related to cardiac  
25 mortality.

Less invasive methods for treating abdominal aortic aneurysms avoid  
many of these problems and additionally result in reduced patient discomfort,  
reduced hospital stays and reduced care intensity.<sup>5</sup> Endovascular grafts have

-5-

been investigated as one example of a less invasive method for the treatment of aneurysmal aortic disease. When compared to open surgery, endovascular grafting provides similar perioperative mortality rates notwithstanding the fact that endovascular grafting is often performed with individuals who are not candidates for open surgery due to one or more medical conditions which preclude such surgery.<sup>1,4</sup> One of the main concerns regarding endovascular grafting is the continued blood flow into the aneurysm after grafting which blood flow is termed in the art as an endoleak.<sup>2</sup> Endoleaks have been reported in from about 7 to about 37% of endovascular aortic aneurysm repairs<sup>3</sup> with some reports placing this number as high as 44%.

Specifically, endovascular grafting requires catheter placement of an endovascular prosthesis at the abdominal aortic aneurysm site. Endoleaks arising after such grafting may be caused by incomplete sealing between the endovascular prosthesis and the aortic wall or by defects within the endovascular prosthesis such as at juncture points between segments of the prosthesis which permit blood flow through the prosthesis itself. In addition, retrograde bleeding from patent lumbar and inferior mesenteric arteries following placement of the endovascular prosthesis in the aorta has also been cited as a potential cause of endoleaks.<sup>6</sup> There is uniform agreement that large endoleaks that lead to aneurysm enlargement necessitate treatment in order to prevent aneurysm rupture. It is also reported that the size of the endoleak does not appear to be a relevant factor for pressure transmission into the aneurysm.<sup>3</sup>

There are a variety of prophylactic and therapeutic treatment regimens for endoleaks reported in the literature. Prophylactic methods of inhibiting endoleaks by embolizing vasculature leading to the aneurysm, evidently with metallic coils, have been suggested and dismissed in an article by Walker, et al.<sup>19</sup> Therapeutic methods for endovascular repair include placement of

-6-

additional stents within the prosthesis; insertion of metallic coils into the aneurysm space to induce thrombosis therein; and embolization of the inferior mesenteric artery using a prepolymer/water soluble contrast agent composition.<sup>18</sup>

5           The goal of such treatments is complete exclusion of the aneurysm from systemic blood flow. While complete exclusion is desirable, a secondary goal is to reduce intraaneurysmal pressure (IAP) from blood flow into the aneurysm to acceptable levels thereby inhibiting the likelihood of rupture. In cases where no endoleaks arose after endovascular grafting, the mean IAP has  
10           been reported to be reduced by about 65%. However, when endoleaks arise, it is reported that the mean IAP, while initially decreasing significantly, stabilized after a week at a reduction of only 22%. Moreover, the use of coils to which purportedly induce thrombosis and thereby reduce IAP have been reported not to have any significant impact on the IAP.

15           In view of existing problems associated with endovascular repair of endoleaks, the accepted treatment for these endoleaks is open surgery. However, the mortality rates for open surgery of endoleaks is higher than either initial open surgery for the abdominal aortic aneurysm or for the initial endovascular repair of the aneurysm.

20           In view of the above, reliable endovascular methods to inhibit endoleaks associated with endovascular graft repair of abdominal aortic aneurysms is desirable. The methods of the present invention fulfills this need.

### SUMMARY OF THE INVENTION

25           This invention is directed to methods for inhibiting endoleaks arising from endovascular repair of abdominal aortic aneurysms.



-7-

In one aspect, the methods of this invention comprise inhibiting endoleaks arising from retrograde bleeding from blood vessels associated with the aneurysmal sac such as the lumbar and inferior mesenteric arteries into the aneurysm sac which permit blood flow through it after endovascular repair of abdominal aortic aneurysms.

Specifically, in one aspect, the methods of this invention involve the *in situ* embolization of blood vessels associated with the aneurysmal sac prior to placement of an endovascular prostheses in the abdominal aorta. Embolization of the blood vessels is achieved by injection of a biocompatible fluid composition into these vessels in a sufficient amount such that upon *in situ* solidification of this composition, blood circulation through these blood vessels and the aneurysmal sac ceases. Preferably, the biocompatible fluid composition comprises a contrast agent to allow the clinician to visualize the embolization process.

In another aspect, the methods of this invention further comprise sealing of endoleaks formed after placement of the endovascular prosthesis by injection of a biocompatible fluid composition at the site of the endoleak which composition *in situ* forms a coherent solid mass which adheres to vascular and/or prosthetic wall to seal the endoleak. These methods are described in U.S. Serial No. 09/273,120, filed on March 19, 1999, and in U.S. Serial No. \_\_\_\_\_, filed concurrently herewith as Attorney Docket No. 018413-249 and entitled "Methods For Treating Endoleaks During Endovascular Repair of Abdominal Aortic Aneurysms" which applications are incorporated herein by reference in their entirety.

In a preferred embodiment, the fluid composition comprises a biocompatible polymer, a biocompatible solvent and a contrast agent to allow the clinician to visualize the procedure.

-8-

In a further preferred embodiment, the contrast agent is a water insoluble contrast agent characterized by having an average particle size of about 10  $\mu\text{m}$  or less.

5 In another preferred embodiment, the fluid composition comprises a biocompatible prepolymer and a contrast agent which, again, is employed to allow the clinician to visualize the procedure. In a further preferred embodiment, the contrast agent is a water insoluble contrast agent characterized by having an average particle size of about 10  $\mu\text{m}$  or less.

10 Accordingly, in one of its method aspects, this invention provides a method for inhibiting endoleaks in a patient arising from endovascular repair of abdominal aortic aneurysms which method comprises:

identifying an abdominal aortic aneurysm in a patient;

15 embolizing blood vessels associated with the aneurysmal sac wherein said embolization comprises delivering a sufficient amount of a biocompatible fluid composition to said vessels under conditions where the fluid composition solidifies thereby embolizing said vessels; and

subsequently endovascularly repairing said aneurysm by catheter delivery of an endovascular prosthesis to the site of said aneurysm thereby inhibiting blood flow into the aneurysm.

20 In another of its method aspects, this invention provides a method for inhibiting endoleaks in a patient arising from endovascular repair of abdominal aortic aneurysms which method comprises:

identifying an abdominal aortic aneurysm in a patient;

25 embolizing blood vessels associated with the aneurysmal sac wherein said embolization comprises delivering a sufficient amount of a biocompatible fluid composition to said vessels under conditions where the fluid composition solidifies thereby embolizing said vessels;

-9-

subsequently endovascularly repairing said aneurysm by catheter delivery of an endovascular prosthesis to the site of said aneurysm thereby inhibiting blood flow into the aneurysm;

identifying one or more endoleaks formed after placement of the  
5 endovascular prosthesis in said patient; and

delivering to the site or sites of endoleaks a sufficient amount of a fluid composition under conditions wherein the fluid composition forms a coherent adhesive mass *in situ* thereby sealing the endoleaks.

Methods further comprising the step of delivering a detectable agent,  
10 such as a contrast agent, through the catheter after it has been inserted into the blood vessels capable of delivering blood flow to the aneurysm sac and detecting the agent to confirm that the catheter has the proper placement prior to delivery of the fluid composition to the blood vessels are also provided.

### DETAILED DESCRIPTION OF THE INVENTION

15 This invention is directed to novel methods for inhibiting endoleaks associated with endovascular repair of abdominal aortic aneurysms. In particular, this invention is directed to methods for inhibiting the formation of endoleaks arising from retrograde bleeding from blood vessels associated with the aneurysmal sac such as the lumbar and inferior mesenteric arteries which  
20 permit blood flow through it after endovascular repair of abdominal aortic aneurysms.

Specifically, the methods of this invention involve the *in situ* embolization of blood vessels associated with the aneurysmal sac prior to placement of an endovascular prostheses in the abdominal aorta. Embolization  
25 of the blood vessels is achieved by injection of either a biocompatible polymer or prepolymer fluid composition into these vessels in a sufficient amount such

-10-

that upon *in situ* solidification of this composition, blood circulation through these blood vessels and the aneurysmal sac ceases.

However, prior to discussing this invention in further detail, the following terms will first be defined:

5           The term "embolizing blood vessels" refers to a process wherein a biocompatible fluid composition is injected (e.g., needle or catheter injection) into the blood vessels such that upon *in situ* solidification of this composition, blood flow through these vessels and the aneurysmal sac ceases. For example, embolization of patent lumbar and/or the inferior mesenteric arteries  
10 stops the flow of blood to or from these vessels to the aneurysmal sac.

          The term "biocompatible polymer" refers to polymers which, in the amounts employed, are non-toxic, chemically inert, and substantially non-immunogenic when used internally in the patient and which are substantially insoluble in blood. Suitable biocompatible polymers include, by way of  
15 example, cellulose acetates<sup>7,10-11</sup> (including cellulose diacetate<sup>9</sup>), ethylene vinyl alcohol copolymers<sup>8,12</sup>, hydrogels (e.g., acrylics), polyacrylonitrile, polyvinylacetate, cellulose acetate butyrate, nitrocellulose, copolymers of urethane/carbonate, copolymers of styrene/maleic acid, and mixtures thereof.<sup>13</sup> Preferably, the biocompatible polymer does not induce chronic  
20 inflammation when employed *in vivo*.

          The particular biocompatible polymer employed is not critical and is selected relative to the viscosity of the resulting polymer solution, the solubility of the biocompatible polymer in the biocompatible solvent, and the like. Such factors are well within the skill of the art.

25           Preferred biocompatible polymers include cellulose diacetate and ethylene vinyl alcohol copolymer. Cellulose diacetate polymers are either commercially available or can be prepared by art recognized procedures. In a preferred embodiment, the number average molecular weight, as determined

-11-

by gel permeation chromatography, of the cellulose diacetate composition is from about 25,000 to about 100,000 more preferably from about 50,000 to about 75,000 and still more preferably from about 58,000 to 64,000. The weight average molecular weight of the cellulose diacetate composition, as  
5 determined by gel permeation chromatography, is preferably from about 50,000 to 200,000 and more preferably from about 100,000 to about 180,000. As is apparent to one skilled in the art, with all other factors being equal, cellulose diacetate polymers having a lower molecular weight will impart a lower viscosity to the composition as compared to higher molecular weight  
10 polymers. Accordingly, adjustment of the viscosity of the composition can be readily achieved by mere adjustment of the molecular weight of the polymer composition.

Ethylene vinyl alcohol copolymers comprise residues of both ethylene and vinyl alcohol monomers. Small amounts (e.g., less than 5 mole percent)  
15 of additional monomers can be included in the polymer structure or grafted thereon provided such additional monomers do not alter the sealing properties of the composition. Such additional monomers include, for example, maleic anhydride, styrene, propylene, acrylic acid, vinyl acetate and the like.

Ethylene vinyl alcohol copolymers are either commercially available or  
20 can be prepared by art recognized procedures. Preferably, the ethylene vinyl alcohol copolymer composition is selected such that a solution of 6 weight percent of the ethylene vinyl alcohol copolymer, 35 weight percent of a tantalum contrast agent in DMSO has a viscosity equal to or less than 60 centipoise at 20°C. As is apparent to one skilled in the art, with all other  
25 factors being equal, copolymers having a lower molecular weight will impart a lower viscosity to the composition as compared to higher molecular weight copolymers. Accordingly, adjustment of the viscosity of the composition as

-12-

necessary for catheter delivery can be readily achieved by mere adjustment of the molecular weight of the copolymer composition.

As is also apparent, the ratio of ethylene to vinyl alcohol in the copolymer affects the overall hydrophobicity/hydrophilicity of the composition which, in turn, affects the relative water solubility/insolubility of the composition as well as the rate of precipitation of the copolymer in an aqueous solution (e.g., blood). In a particularly preferred embodiment, the copolymers employed herein comprise a mole percent of ethylene of from about 25 to about 60 and a mole percent of vinyl alcohol of from about 40 to about 75. These compositions provide for requisite precipitation rates suitable for use in sealing endoleaks arising from endovascular repair of an abdominal aortic aneurysm.

The term "contrast agent" refers to a biocompatible (non-toxic) radiopaque material capable of being monitored during injection into a mammalian subject by, for example, radiography or fluoroscopy. The contrast agent can be either water soluble or water insoluble. Examples of water soluble contrast agents include metrizamide, iopamidol, iothalamate sodium, iodamide sodium, and meglumine.

The term "water insoluble contrast agent" refers to a water insoluble (i.e., has a water solubility of less than 0.01 mg/ml at 20°C), radiopaque material capable of being monitored during injection into a mammalian subject by, for example, radiography or fluoroscopy. Examples of water insoluble contrast agents include tantalum, tantalum oxide and barium sulfate, which are commercially available in the proper form for *in vivo* use. Methods for preparing such water insoluble biocompatible contrast agents having an average particle size of about 10  $\mu$ m or less are described below. Other water insoluble contrast agents include gold, tungsten and platinum.

-13-

The term "biocompatible solvent" refers to an organic material liquid at least at body temperature of the mammal in which the biocompatible polymer is soluble and, in the amounts used, is substantially non-toxic. Suitable biocompatible solvents include, by way of example, ethanol, acetone, dimethylsulfoxide, analogues/homologues of dimethylsulfoxide, ethyl lactate, and the like. Aqueous mixtures with the biocompatible solvent can also be employed provided that the amount of water employed is sufficiently small that the dissolved polymer precipitates upon contact with the blood. Preferably, the biocompatible solvent is dimethylsulfoxide (DMSO).

10 The term "encapsulation" as used relative to the contrast agent being encapsulated in the polymer precipitate is not meant to infer any physical entrapment of the contrast agent within the precipitate such as a capsule encapsulates a medicament. Rather, this term is used to mean that an integral coherent precipitate forms which does not separate into individual  
15 components.

The term "adheres to" as used herein means that the composition formed *in situ* retains the position/location where the polymer mass formed after injection and thereby functions to seal the blood vessels. This term does not necessarily infer that the composition acts as an adhesive although in the  
20 case of, for example, a cyanoacrylate prepolymer, the solid composition formed may, in fact, be adhesive.

The term "biocompatible prepolymer" refers to materials which polymerize *in situ* to form a polymer and which, in the amounts employed, are non-toxic, chemically inert, and substantially non-immunogenic when used  
25 internally in the patient and which are substantially insoluble in blood. Suitable biocompatible prepolymers include, by way of example, cyanoacrylates<sup>14,15,16</sup>, hydroxyethyl methacrylate, silicone prepolymers, and the like. The prepolymer can either be a monomer or a reactive oligomer<sup>16</sup>.

-14-

Preferably, the biocompatible prepolymer does not induce chronic inflammation when employed *in vivo*.

### Compositions

The compositions used in the methods of this invention are

5 biocompatible fluid compositions characterized by the fact that these compositions form a coherent mass *in vivo* which adheres to the vascular wall of the blood vessels thereby ceasing the blood flow through these vessels and the aneurysmal sac. The fluid compositions employed in the methods of this invention are polymer or prepolymer compositions prepared by conventional

10 methods whereby each of the components is added and the resulting composition mixed or stirred together until the overall composition is substantially homogeneous.

Fluid polymer compositions preferably comprise a biocompatible polymer, a biocompatible solvent and optionally a contrast agent. Such

15 compositions can be prepared by adding sufficient amounts of the biocompatible polymer to the biocompatible solvent to achieve the effective concentration for the polymer composition. Preferably, the polymer composition will comprise from about 2.5 to about 12.0 weight percent of the biocompatible polymer composition based on the total weight of the polymer

20 composition and more preferably from about 4 to about 5.4 weight percent. If necessary, gentle heating and stirring can be used to effect dissolution of the biocompatible polymer into the biocompatible solvent, e.g., 12 hours at 50°C.

When employed, sufficient amounts of the contrast agent are added to the biocompatible polymer/solvent composition to achieve the effective

25 concentration for the complete composition. Preferably, the composition will comprise from about 10 to about 40 weight percent of the contrast agent and more preferably from about 20 to about 40 weight percent and even more



-15-

preferably about 30 weight percent. Insofar as the contrast agent may not be soluble in the biocompatible solvent (e.g., a water insoluble contrast agent), stirring is employed to effect homogeneity of the resulting suspension.

5 In order to enhance formation of the suspension, the particle size of the water insoluble contrast agent is preferably maintained at about 10  $\mu\text{m}$  or less and more preferably at from about 1 to about 5  $\mu\text{m}$  (e.g., an average size of about 2  $\mu\text{m}$ ). In one preferred embodiment, the appropriate particle size of the contrast agent is prepared, for example, by fractionation. In such an embodiment, a water insoluble contrast agent such as tantalum having an  
10 average particle size of less than about 20 microns is added to an organic liquid such as ethanol (absolute) preferably in a clean environment. Agitation of the resulting suspension followed by settling for approximately 40 seconds permits the larger particles to settle faster. Removal of the upper portion of the organic liquid followed by separation of the liquid from the particles  
15 results in a reduction of the particle size which is confirmed under an optical microscope. The process is optionally repeated until a desired average particle size is reached.

When no contrast agent is employed, the biocompatible solvent is preferably employed at a concentration of from 88 to about 97.5 weight  
20 percent of the biocompatible polymer composition based on the total weight of the polymer composition and more preferably from about 90 to about 95 weight percent.

When a contrast agent is employed, the biocompatible solvent is preferably employed at a concentration of from 52 to 87.5 weight percent  
25 based on the total weight of the composition; more preferably from about 54.8 to about 76 weight percent; and even more preferably 64.8 to about 66 weight percent. Typical examples of suitable concentrations of individual components are given in the table below:

-16-

Example	Polymer	Solvent	Contrast Agent
A	2.5 weight %	97.5 weight %	--
B	8 weight %	92 weight %	--
C	2.5 weight %	87.5 weight %	10 weight %
D	8 weight %	82 weight %	10 weight %
E	2.5 weight %	57.5 weight %	40 weight %
F	8 weight %	52 weight %	40 weight %
G	8 weight %	72 weight %	20 weight %
H	2.5 weight %	67.5 weight %	30 weight %
I	8 weight %	62 weight %	30 weight %
J	4 weight %	66 weight %	30 weight %
K	5.4 weight %	64.6 weight %	30 weight %

The particular order of addition of components to the biocompatible solvent is not critical and stirring of the resulting solution/suspension is conducted as necessary to achieve homogeneity of the composition. Preferably, mixing/stirring of the composition is conducted under an anhydrous atmosphere at ambient pressure. The resulting composition is heat sterilized and then stored preferably in sealed amber bottles or vials until needed.

Each of the polymers recited herein is commercially available but can also be prepared by methods well known in the art. For example, polymers are typically prepared by conventional techniques such as radical, thermal, UV,  $\gamma$  irradiation, or electron beam induced polymerization employing, as necessary, a polymerization catalyst or polymerization initiator to provide for the polymer composition. The specific manner of polymerization is not

-17-

critical and the polymerization techniques employed do not form a part of this invention.

In order to maintain solubility in the biocompatible solvent, the polymers described herein are preferably not cross-linked.

5           The fluid compositions described herein can also be prepolymer compositions which preferably comprise a biocompatible prepolymer and optionally a contrast agent. When a contrast agent is employed, such compositions can be prepared by adding sufficient amounts of the contrast agent to the solution (e.g., liquid prepolymer) to achieve the effective  
10           concentration for the complete composition. Preferably, the prepolymer composition will comprise from about 10 to about 40 weight percent of the contrast agent and more preferably from about 20 to about 40 weight percent and even more preferably about 30 weight percent. When the contrast agent is not soluble in the biocompatible prepolymer composition, stirring is  
15           employed to effect homogeneity of the resulting suspension. In order to enhance formation of the suspension, the particle size of the contrast agent is preferably maintained at about 10  $\mu\text{m}$  or less and more preferably at from about 1 to about 5  $\mu\text{m}$  (e.g., an average size of about 2  $\mu\text{m}$ ).

20           When the prepolymer is liquid, the use of a biocompatible solvent is not absolutely necessary but may be preferred to provide for an appropriate viscosity, etc. in the composition. Preferably, when employed, the biocompatible solvent will comprise from about 30 to about 90 weight percent of the biocompatible prepolymer composition based on the total weight of the prepolymer composition and more preferably from about 60 to about 80  
25           weight percent. When a biocompatible solvent is employed, the prepolymeric composition typically comprises from about 10 to about 70 weight percent of the prepolymer, preferably from about 10 to about 50 weight percent, based

-18-

on the total weight of the composition. Typical examples of suitable concentrations of individual components are given in the table below:

Example	Prepolymer	Solvent	Contrast Agent
L	100 weight %	--	--
M	90 weight %	--	10 weight %
N	80 weight %	--	20 weight %
O	70 weight %	--	30 weight %
P	60 weight %	--	40 weight %
Q	70 weight %	30 weight %	--
R	10 weight %	90 weight %	--
S	60 weight %	30 weight %	10 weight %
T	30 weight %	30 weight %	40 weight %
U	40 weight %	30 weight %	40 weight %
V	60 weight %	10 weight %	30 weight %

In a particularly preferred embodiment, the prepolymer is a cyanoacrylate ester which is preferably employed in the absence of a biocompatible solvent. When so employed, the cyanoacrylate composition is selected to have a viscosity of from about 5 to about 20 centipoise at 20°C.

The particular order of addition of components is not critical and stirring of the resulting suspension is conducted as necessary to achieve homogeneity of the composition. Preferably, mixing/stirring of the composition is conducted under an anhydrous atmosphere at ambient pressure. The resulting composition is sterilized and then stored preferably in sealed amber bottles or vials until needed.

-19-

In one preferred embodiment, the contrast agent employed is the commercially available Lipiodol formulation which contains an iodinated poppyseed oil. Preferably the Lipiodol formulation is employed at a weight ratio of about 1:1 to 3:1 relative to the prepolymer (e.g., cyanoacrylate). This composition may retard the polymerization rate of cyanoacrylate prepolymers to provide a measure of control over the polymerization rate.

### Methods

The compositions described above can then be employed in methods for the embolization of blood vessels associated with the aneurysmal sac including lumbar and inferior mesenteric arteries thereby inhibiting the formation of endoleaks caused by blood flow between these vessels and the aneurysm sac before endovascular repair of abdominal aortic aneurysms by an endovascular prosthesis.

Specifically, endovascular repair of such aneurysms involves the introduction of an endovascular prosthesis into the abdominal aortic aneurysm which is an art recognized procedure described, for example, by Parodi.<sup>17</sup> In one embodiment, this procedure consists of dissection of the femoral artery at the groin and introduction of an endovascular prosthesis inside the abdominal aortic aneurysm using a suitable catheter. Upon insertion, the prosthesis excludes the aneurysm sac from the systemic vascular circulation thereby repairing the aneurysm. Suitable endovascular prostheses for endovascular repair of abdominal aortic aneurysms are well known in the art and are described, for example, by Beebe, et al.<sup>5</sup> Such prostheses, by themselves, do not form part of this invention. Similarly, catheters for delivering such endovascular prostheses to the site of the abdominal aortic aneurysm are also well known in the art and are commercially available. Such catheters, by themselves, also do not form part of this invention.

-20-

In the methods of this invention, a sufficient amount of the fluid composition described above is introduced into the blood vessels preferably under fluoroscopy so that embolization of the blood vessels can be visualized. The specific amount of fluid composition employed is dictated by the total size  
5 of the blood vessel, and other factors such as the concentration of polymer/prepolymer in the composition, the rate of solids formation, etc. Such factors are well within the skill of the art.

Prior to sealing the potential endoleak in the manner described above, the clinician would first identify the site or sites of the potential endoleak  
10 which typically include lumbar and inferior mesenteric arteries associated with the aneurysm itself.<sup>19</sup>

Access to these sites of blood vessels where the fluid composition is to be delivered can be achieved by endovascular catheter access via the femoral artery which is well known in interventional radiology practice or by a needle.  
15 After access is achieved, delivery of the fluid composition proceeds as described above.

One particularly preferred method for catheter delivering the compositions described in the methods of this invention to the desired site in the blood vessels is via a small diameter medical catheter. The particular  
20 catheter employed is not critical provided that polymeric catheter components are compatible with the fluid composition (i.e., the catheter components will not readily degrade in the fluid composition). In this regard, it is preferred to use polyethylene in the catheter components because of its inertness in the presence of the fluid composition described herein. Other materials  
25 compatible with the fluid compositions can be readily determined by the skilled artisan and include, for example, other polyolefins, fluoropolymers (e.g., Teflon<sup>TM</sup>), silicone, etc.

-21-

Another particularly preferred method for the catheter injection of the polymer composition of this invention is described by Greff, et al., U.S. Patent No. 5,830,178 which issued on November 3, 1998 and which is incorporated herein by reference in its entirety.

5           When a fluid composition comprising a biocompatible polymer is introduced into the blood vessel, the biocompatible solvent diffuses rapidly into the blood and a solid coherent mass forms *in situ* which precipitate is the water insoluble polymer with any contrast agent encapsulated therein. Without being limited to any theory, it is believed that initially, a soft gel to  
10           spongy solid precipitate forms upon contact with the blood which mass adheres to the vascular wall thereby embolizing the blood vessel.

          When a fluid composition comprising a biocompatible prepolymer is introduced into the blood vessel, the prepolymer polymerizes *in situ* to form a solid coherent mass or film with any water insoluble contrast agent  
15           encapsulated therein. This mass adheres to the vascular wall thereby embolizing the vessel.

          Embolization of the blood vessels by the fluid composition can be confirmed by injecting an independent contrast agent such as iopamidol (50:50 mixture with saline) into the blood flow of the aorta. Failure of this contrast  
20           agent to reach or flow through the occluded vessels as visualized by fluoroscopy confirms embolization of these blood vessel.

          The embolization of blood vessels can be conducted as an initial protocol during the surgical repair of the abdominal aortic aneurysm or in a separate surgical procedure conducted prior to the surgical repair. All that is  
25           required is identifying an abdominal aortic aneurysm in the patient, identifying the vessels associated with the aneurysm, and introduction of the fluid composition to embolize the blood vessels that cause blood flow with the

-22-

aneurysm sac after placement of the endovascular prosthesis thereby causing formation of endoleaks.

### Utility

5 The methods described herein are useful for inhibiting the formation of endoleaks arising from blood flow to or from blood vessels associated with the aneurysmal sac including the lumbar and inferior mesenteric arteries after endovascular repair of abdominal aortic aneurysms. Accordingly, these methods find use in human and other mammalian subjects requiring endovascular repair of abdominal aortic aneurysms.

10 Additionally, when a water insoluble contrast agent is employed, the stability of the closure can be monitored weeks, months or even years after sealing by non-invasive fluoroscopic techniques. Resealing of the blood vessels is also facilitated by the presence of the water insoluble contrast agent which permits the clinician to readily identify the site of previously treated  
15 blood vessel.

It is contemplated that the procedures set forth above can be employed for inhibiting the formation of endoleaks arising from insertion of an endovascular prosthesis at vascular sites other than the abdominal aorta. Such prostheses could be used to repair aneurysms and other vascular diseases at  
20 vascular sites such as peripheral vessels.

Kit of parts using the components of the methods of this invention are also contemplated by this invention. Such kits comprise the following components:

(a) a fluid composition which comprises a composition selected  
25 from the group consisting of (i) a biocompatible polymer and a biocompatible solvent and (ii) a biocompatible prepolymer and a water insoluble contrast agent which fluid composition forms a coherent mass in the presence of blood



-23-

which mass adheres to the vascular surface and/or the surface of the endovascular prosthesis;

(b) a catheter suitable for delivering the fluid composition to the vascular site of blood flow to or from the aneurysmal sac; and

5 (c) a catheter suitable for delivering an endovascular prosthesis to the aneurysm.

In a preferred embodiment, this kit further comprises an endovascular prosthesis.

In another embodiment, this kit comprises the following components:

10 (a) a fluid composition which comprises a composition selected from the group consisting of (i) a biocompatible polymer and a biocompatible solvent and (ii) a biocompatible prepolymer and a water insoluble contrast agent which fluid composition forms a coherent mass in the presence of blood which mass adheres to the vascular surface and/or the surface of the  
15 endovascular prosthesis;

(b) a catheter suitable for delivering the fluid composition to the vascular site of blood flow to or from the aneurysmal sac; and

(c) an endovascular prosthesis.

The following examples are set forth to illustrate the claimed invention  
20 and are not to be construed as a limitation thereof.

### EXAMPLES

Unless otherwise stated, all temperatures are in degrees Celsius. Also, in these examples and elsewhere, the following abbreviations have the following meanings:

25	atm	=	atmospheres
	cc	=	cubic centimeter
	cm	=	centimeter
	DMSO	=	dimethylsulfoxide

-24-

	EVOH	=	ethylene vinyl alcohol copolymer
	g	=	gram
	hrs	=	hours
	IM	=	intramuscularly
5	in.	=	inch
	IU	=	international units
	IV	=	intravenously
	kg	=	kilogram
	mg	=	milligram
10	min.	=	minute
	mL	=	milliliter
	mm	=	millimeter
	PTFE	=	polytetrafluoroethylene
	sec.	=	seconds
15	SQ	=	subcutaneously
	$\mu\text{m}$	=	micron

Example 1

The purpose of this example is to demonstrate the preparation of a fluid polymer composition useful in the methods of this invention.

Specifically, an EVOH polymer composition was prepared as follows:

Composition

- A) 8 g EVOH;
- B) 30 g tantalum having an average particle size of about 3  $\mu\text{m}$  (narrow size distribution); and
- C) 100 mL DMSO.

Component A) was added to Component C) at 50°C and stirred for 2 hrs on a hot plate under an argon blanket. To this resulting composition was added Component B and the resulting mixture was mixed until homogeneous.

-25-

Example 2

This example illustrates a protocol for sealing of endoleaks which may arise from endovascular repair of an abdominal aortic aneurysm in a dog model. In this example, potential endoleaks are sealed by embolizing blood vessels leading from the aneurysm sac which would allow blood flow from the aneurysm. The following illustrates the protocol which can be employed:

Equipment Used

0.035/0.038 3J Guide Wires (Cook, Bloomington, IN)  
5 F Angiographic Catheters (Pigtail - Royal Flush II; Cook,  
Bloomington, IN)  
10-14F Introducer Sheaths (Checkflow sheath; Cook,  
Bloomington, IN)  
Angioplasty Balloon Catheters (10x2/ 10x4/ 10x6/ 16x2/  
18x2/22x2) - (Blue Max and XXL; Meditech,  
Massachusetts)  
4 mm PTFE Graft (Gore and Associates, Flagstaff, Ariz)  
4mm Aortic Punch (Medtronic, Minneapolis, Minn)  
Palmaz Stents: P104, P4014, P5014 (Johnson and Johnson  
Interventional Systems, New Jersey)  
Infusion Catheters (Easy Rider™ 3F, Micro Therapeutics,  
Irvine, CA)  
Microguide Wire (Silver Speed™, Micro Therapeutics,  
Irvine, CA)  
Composition of Example 1  
Hypaque 76 (Nycomed, Princeton, New Jersey)  
5F Guiding Catheter (Cordis, Miami Lakes, FL)

Pre-surgical Procedures

The animal is fasted 24 hrs prior to surgery and then pre-anesthetized with 0.01 mg/kg Glycopyrrolate SQ followed by anesthetization with a combination of Butorphanol, Xylazine, and Telazol. This combination is

-26-

given such that 6.6 /kg Telazol is given IM. Next, the animal is incubated and connected to Isoflurane gas anesthesia of 1-3%.

A 20 gauge catheter is placed into the cephalic vein of the animal and 0.9% saline is administered intravenously at a rate of 1-4 mL/kg/hr and then  
5 15 mL blood is collected for CBC liver profile.

A standard sterile surgical preparation and draping is utilized. The right carotid or femoral artery is exposed via vessel cutdown and distal and proximal hemostatic loops are placed. An arteriotomy is then performed and the introducer sheath (10-12F) is advanced into the artery lumen. The sheath  
10 and artery are then secured.

After the introducer is placed, the animal is IV heparinized with 100 units of heparin/kg of body weight.

A 5F measuring pigtail catheter is introduced over a standard 0.035 inch, 3 mm "J" guide wire. A flush anteroposterior projection aortogram is  
15 obtained with use of contrast media, and the mediolateral diameter of the dog infrarenal aorta is measured with the use of the markers on the pigtail as standardization. A flat film X-ray is required during the contrast arteriography.

In accordance of the measurements of the infrarenal aorta, a Palmaz  
20 stent is deployed into the infrarenal aorta on a 10 mm diameter, 4 cm long angioplasty balloon with use of fluoroscopic guidance. Then the infrarenal aorta is overdilated to 1.5-2.0 its measured normal diameter in the dog at 6-8 atm. using a standard pressure gauge for a single inflation lasting 30 sec.

The balloon is removed over a wire and replaced with the measuring  
25 pigtail catheter. A repeat aortogram is obtained and the abdominal aortic aneurysm is measured in the animal. A flat film with and without contrast media injections is obtained with all prostheses in the field of view.

-27-

A 5F guiding catheter is then introduced and passes to the site of the aneurysm. Under fluoroscopy, contrast is injected to visualize the arteries coming from the aneurysm sac (e.g., lumbar, inferior mesenteric arteries). A 3F microcatheter with a microguide wire passes through the guiding catheter and each identified artery is catheterized. The liquid embolic agent is injected into each artery to seal the vessel and prevent any blood flow.

To construct the endovascular graft, a 4 mm PTFE graft is dilated with a 10 mm x 6 cm balloon catheter. A balloon expandable Palmaz stent (P104) is secured to the proximal end of the graft with two sutures. This endovascular graft is mounted on 10 mm x 6 cm balloon catheters and backloaded into the introducer sheath. The graft is proximally perforated with a 4 mm aortic punch which produces a graft defect that is the source of the endoleak. This endograft is placed coaxially within the aneurysm and is dilated with a catheter balloon to a final graft diameter of 9 mm. The balloon is removed and another Palmaz stent (P104) is secured to the distal end of the endograft.

The balloon is again removed over a wire and replaced with the measuring pigtail catheter. A repeat aortogram is obtained and the abdominal aortic aneurysm is measured in the animal. A flat film with and without contrast media injections is obtained with the prosthesis in the field of view. The aortogram shows no leakage of blood through the punch hole defect into the embolized arteries or retrograde flow from the embolized arteries into the aneurysmal sac.

Upon completion, the arteriotomy is closed with interrupted polypropylene sutures and the surrounding tissue is sutured. The animal is allowed to recover before being returned to a cage.

At the conclusion of surgery, the animal is given approximately 25,000 IU/kg procaine and benzathine penicillin SQ.

-28-

Post-operatively, the animal receives 325 mg/day of aspirin for 8 weeks and ampicillin 1 g/day for 3 days.

After 1 week, a CT-scan with dye on the dog shows no endoleaks associated with the abdominal aortic aneurysm's endograft.

5

### Example 3

This example illustrates the procedures used to access a simulated endoleak within the aneurysm sac after placement of the prosthesis within the abdominal aortic aneurysm (AAA). Specifically, this example employs the following protocol.

10

A 25 kg male dog was prepared and anesthetized per Example 2 above. An abdominal midline incision was then made and the descending aorta exposed. A 15 mm arteriotomy was made in the aorta and a patch of fascia was sutured onto this opening creating an aneurysm of a size of about 4.5 x 3.5 x 4.0 cm. Three 4F Fogarty balloon catheters were placed into the aneurysm via the carotid artery under fluoroscopy and each balloon catheter was then filled with contrast solution comprising 50:50 saline:Hypaque 76 (0.25 cc, 0.25 cc and 0.5 cc respectively). A 12 mm x 5 cm Wall stent graft was placed within the aorta and over the aneurysm opening. To access the aneurysm sac through the graft, a 6 F guide catheter was placed into the aorta to the graft via the femoral artery and a 22 G x 40 cm needle introduced through the guide catheter. The needle tip was bent about 45 degrees. Under fluoroscopy, the graft wall was punctured and the needle tip advanced into the aneurysm sac. Each of the three filled balloons was successfully located and punctured to release the contrast agent which was visualized via fluoroscopy.

15

20

25

To complete this simulation, a sufficient amount of the composition of Example 1 was then injected through the needle to fill the aneurysm sac. This composition, upon contact with the blood in the aneurysm sac solidified.

-29-

From the foregoing description, various modifications and changes in the above described methods will occur to those skilled in the art. All such modifications coming within the scope of the appended claims are intended to be included therein.

-30-

**WHAT IS CLAIMED IS:**

1. A method for inhibiting endoleaks in a patient arising from endovascular repair of abdominal aortic aneurysms which method comprises:

identifying an abdominal aortic aneurysm in a patient;

5 embolizing blood vessels associated with the aneurysmal sac wherein said embolization comprises delivering through a microcatheter a sufficient amount of a biocompatible fluid composition to said vessels under conditions where the fluid composition solidifies thereby embolizing said blood vessels; and

10 subsequently endovascularly repairing said aneurysm by catheter delivery of an endovascular prosthesis to the site of said aneurysm thereby inhibiting blood flow into the aneurysm.

2. The method of Claim 1 which further comprises the steps of:

15 identifying one or more endoleaks after placement of the endovascular prosthesis in said patient; and

delivering through a microcatheter to the site or sites of endoleaks a sufficient amount of a fluid composition under conditions wherein the fluid composition forms a coherent adhesive mass *in situ* thereby sealing the endoleaks.

20 3. A method for sealing endoleaks formed after placement of a an endovascular prosthesis in a mammal which method comprises the steps of:

identifying an abdominal aortic aneurysm in a patient;

25 endovascularly repairing said aneurysm by catheter delivery of an endovascular prosthesis to the site of said aneurysm thereby inhibiting blood flow into the aneurysm;



-31-

subsequently, identifying one or more endoleaks after placement of the endovascular prosthesis in said patient; and

delivering through a microcatheter to the site or sites of endoleaks a sufficient amount of a fluid composition under conditions wherein the fluid composition forms a coherent adhesive mass *in situ* thereby sealing the endoleaks.

4. The method according to Claims 1 or 3 wherein the fluid composition comprises a biocompatible polymer and a biocompatible solvent.

5. The method according to Claim 4 wherein said biocompatible polymer is selected from the group consisting of cellulose acetate polymers, ethylene vinyl alcohol copolymers, and polyacrylates.

6. The method according to Claim 5 wherein said biocompatible polymer is a cellulose acetate polymer or an ethylene vinyl alcohol copolymer.

7. The method according to Claim 4 wherein said biocompatible solvent is selected from the group consisting of dimethylsulfoxide, ethanol, ethyl lactate, and acetone.

8. The method according to Claim 7 wherein said biocompatible solvent is dimethylsulfoxide.

9. The method according to Claim 4 wherein the composition further comprises a contrast agent.

-32-

10. The method according to Claim 9 wherein said contrast agent is a water insoluble contrast agent.

11. The method according to Claim 10 wherein said water insoluble contrast agent is selected from the group consisting of tantalum, tantalum  
5 oxide, tungsten, and barium sulfate.

12. The method according to Claim 10 wherein said water insoluble contrast agent is characterized by having an average particle size of about 10  $\mu\text{m}$  or less.

13. The method according to Claim 9 wherein said contrast agent is  
10 a water soluble contrast agent.

14. The method according to Claim 13 wherein said water soluble contrast agent is selected from the group consisting of metrizamide, iopamidol, iothalamate sodium, iodamide sodium, and meglumine.

15. The method according to Claims 1 or 3 wherein said  
15 composition comprises a biocompatible prepolymer.

16. The method according to Claim 15 wherein said biocompatible prepolymer composition further comprises a contrast agent.

17. The method according to Claim 16 wherein said contrast agent is a water insoluble contrast agent.

-33-

18. The method according to Claim 17 wherein said water insoluble contrast agent is selected from the group consisting of tantalum, tantalum oxide, tungsten, and barium sulfate.

5 19. The method according to Claim 17 wherein said water insoluble contrast agent is characterized by having an average particle size of about 10  $\mu\text{m}$  or less.

20. The method according to Claim 16 wherein said contrast agent is a water soluble contrast agent.

10 21. The method according to Claim 20 wherein said water soluble contrast agent is selected from the group consisting of metrizamide, iopamidol, iothalamate sodium, iodamide sodium, and meglumine.

22. The method according to Claim 16 wherein the biocompatible prepolymer is selected from the group consisting of cyanoacrylates, hydroxyethyl methacrylate and silicone prepolymers.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/07398

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 51/00; A61M 36/14

US CL : 424/1.29

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/1.11, 1.29, 9.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS, MEDLINE, USPATFULL, EMBASE, CAPLUS, EAST

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,695,480 A (EVANS et al) 09 December 1997, see entire document, especially, abstract; columns 3-4, lines 15-68 and 1-34, respectively; pages 8-9, lines 33-68 and 1-56, respectively.	1-22
Y	WALKER S.R. et al. A Study on the Patency of the Inferior Mesenteric and Lumbar Arteries in the Incidence of Endoleak Following Endovascular Repair of Infra-renal Aortic Eneurysms, Clinical Radiology, pages 593-595, especially, page 593, column 2 and page 594, third through fifth paragraphs.	1-22

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* & * document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

09 MAY 2000

Date of mailing of the international search report

28 JUL 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231


Facsimile No. (703) 305-3230

Authorized officer

D. Jones

Telephone No.

(703) 308-1235



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/07398

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	VAN SCHIE et al, Successful Embolization of Persistent Endoleak From a Patent Inferior Mesenteric Artery, J. Endovasc. Surg., 1997, Vol. 4, pages 312-315, especially, abstract; page 313, Figure 1, and pages 313-314, bridging paragraph.	1-22
Y	US 5,580,568 A (GREFF et al) 03 December 1996, see entire document, especially, column 6, lines 40-48; column 4, lines 60-68; column 4, lines 48-57; column 5, lines 51-68; column 6, lines 1-38; and columns 8-9, Example 3.	1-22

**THIS PAGE BLANK (USPTO)**